Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
¥ 1426
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Immuno-Biological Laboratories Co., Ltd. engages in the research, development, manufacturing, and supply of various immunological research reagents worldwide. The company offers ELILSA, an assay kit to quantitatively measure targeted substances; and support research services on Alzheimer's disease, metabolic syndrome, and cancer, as well as customized services for production of customized antibodies and development of ELISA...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is overpriced on P/E, 'expensive
Data is available to registered users only
Buy
Sell